Humana Inc. (HUM) is making bold strides in the U.S. healthcare sector, expanding its focus on musculoskeletal (MSK) care as part of a larger shift towards value-based care (VBC). With the MSK market projected to reach US$32 billion and grow at a compound annual growth rate (CAGR) of 6% through 2033, Humana’s initiatives align with key healthcare trends while addressing the needs of an ageing population and patients with chronic conditions.
A Growing Market for MSK Care
The demand for musculoskeletal care is on the rise, driven by the prevalence of conditions such as osteoarthritis and rheumatoid arthritis, along with advancing therapies like regenerative medicine and robotics. In 2024, the U.S. MSK market was valued at US$20 billion, playing a significant role in the broader expansion of chronic condition management.
Orthopaedic care, a subset of the MSK market, was valued at US$59 billion in 2024 and is projected to grow at 4% annually. This growth is largely attributed to the shift towards ambulatory surgical centres and the adoption of robotic-assisted surgeries, both of which contribute to improving patient outcomes and reducing costs.
Humana’s focus on value-based care plays a crucial role in this transformation. Unlike traditional fee-for-service models, VBC rewards healthcare providers for improving patient outcomes while reducing costs. For MSK care, the emphasis lies on preventive care, multidisciplinary coordination, and the use of advanced digital tools like telemedicine and wearable devices. As an example of its success, Humana’s Medicare Advantage (MA) members in VBC arrangements had 25.8% lower medical costs in 2023 compared to those under Original Medicare.
Key Initiatives Driving Humana’s Strategy
Humana’s approach to MSK care is deeply integrated into its broader strategy of aligning with healthcare trends and patient needs. A few pivotal initiatives include:
Partnerships for Coordinated Care
The company has built partnerships with Vori Health, HOPCo, and TailorCare, establishing a nationwide network to deliver coordinated care. These collaborations ensure patients receive early intervention, personalised treatment plans, and continuous monitoring to better manage chronic conditions. Notably, TailorCare has announced its expansion to Dallas and Denver in late 2025, which will bring high-value care to areas with significant demand.
Leveraging Digital Health
Digital health solutions are a cornerstone of Humana’s MSK care strategy. By integrating AI-powered platforms like Hinge Health and Sword Health, the company facilitates remote physical therapy, real-time patient monitoring, and data-driven decision-making. This focus on digital health adoption reflects a broader market trend, with the sector expected to grow at a 17.7% CAGR through 2030.
Cost Savings and Reinvestment
Humana’s VBC model has already delivered measurable cost savings, which the company reinvests into member benefits such as lower premiums, home care services, and prescription delivery. For instance, in Q4 2024, the company’s CenterWell segment generated US$10 million in revenue, reflecting the financial sustainability of its integrated care offerings.
Expanding Home-Based Care
Humana is also prioritising home and community-based care for post-acute MSK patients. Through partnerships like OneHome in Florida and Texas, the company is reducing hospital readmissions and improving care coordination. This aligns with the Centres for Medicare & Medicaid Services (CMS) push for home-based care models, which are expected to become a US$100 billion market by 2030.
Financial Performance and Future Prospects
Humana’s financial performance underscores its ability to execute its long-term strategy. In Q1 2025, the company reported an 8.4% revenue increase to US$32.11 billion, with an adjusted earnings per share (EPS) of US$11.58, exceeding expectations. The company also demonstrated its financial resilience with a US$1.25 billion debt offering and a dividend of US$0.885 per share.
Additionally, Humana’s focus on Medicaid expansion and dual-eligible special needs plans (D-SNPs) provides a stable revenue base. For example, its intention to secure a D-SNP contract in Illinois represents an opportunity to further scale its MSK care model into new markets.
Challenges Ahead
Despite its achievements, Humana faces potential challenges. Regulatory scrutiny of Medicare Advantage remains a concern, as CMS policy changes could affect reimbursement rates. Moreover, implementing VBC models requires aligning incentives across providers and payers, which can be complex. However, Humana’s decade-long experience in VBC and its strong partnerships provide a solid foundation to navigate these challenges.
A Strategic Vision for the Future
Humana’s expansion into MSK care is a calculated move to address macro healthcare trends while creating value for patients and investors alike. By targeting a high-growth market with value-based, technology-driven solutions, the company is well-positioned to capture sustained earnings growth in a rapidly evolving sector. As the U.S. healthcare landscape continues to shift towards value-based care, Humana’s strategic leadership in MSK programs is likely to solidify its position as a transformative force in the industry.
Read the source
